AI in Drug Discovery: Data Quality, Not Quantity, Is the Bottleneck

Two important essays on AI in drug discovery landed in August. Both are worth your time. Both have the right intuitions. And one of them is subtly framing the wrong problem, in my opinion. The first is the Nature Reviews Drug Discovery review by Andreas Bender, Morgan Thomas, Jack Scannell, David Shaywitz, Gian Marco Ghiandoni, Joe Greener, and colleagues: "Artificial intelligence in drug…